Clinical Trial

A Multi-center, Ambispective Cohort Study to Evaluate the Impact of Iptacopan for Adult Patients With PNH in China

Study acronym: PNH-NIS
Recruiting
View on ClinicalTrials.gov →
Summary
The implementation of new standards for the management of PNH and the use of iptacopan in patients with PNH are expected to change the treatment landscape and improve the overall prognosis of patients. Based on these backgrounds, we plan to conduct a real-world study of iptacopan to further evaluate its impact on treatment-related outcomes, disease management, and healthcare resource utilization in Chinese patients with PNH.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-04-16; most recent amendment 2026-05-28.
Status change: Not Yet Recruiting → Recruiting 2025-06-11
Trial Details
NCT Number NCT06931691
Lead Sponsor Novartis Pharmaceuticals
Conditions Paroxysmal Nocturnal Hemoglobinuria
Enrollment 80 participants
Start Date 2025-06-10
Primary Completion 2027-04-21 (estimated)
Study Completion 2027-04-21 (estimated)
Updated on ClinicalTrials.gov 2026-06-01